We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ekf Diagnostics Holdings Plc | LSE:EKF | London | Ordinary Share | GB0031509804 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.65 | 2.19% | 30.30 | 30.00 | 30.60 | 30.70 | 30.00 | 30.70 | 245,917 | 16:35:02 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Med, Dental, Hosp Eq-whsl | 52.61M | 2.35M | 0.0052 | 57.69 | 136.48M |
Date | Subject | Author | Discuss |
---|---|---|---|
02/12/2020 11:10 | Last time I did Einstein you were on the opposite side of the fence and we both know who got the last laugh. Keep watching this space fella. There you go old chap. | tongosti | |
02/12/2020 11:06 | Do I detect a touch of humility in your post Mr Market Please let us know when you feel it's worth investing her Toodle pip old chap | chris16041 | |
02/12/2020 10:20 | For once I like this board in the sense that multiple bullish posts taking place every single morning are missing for a few days. Coupled with a bit of a more stable share price (still weak as it is vis-à-vis the larger market) is a not necessarily a bad thing. Sitting this all out at the moment - mainly due to the undetermined nature of Mr Market's price action - but watching v closely. | tongosti | |
02/12/2020 07:29 | Only a small initial order but positive all the same."In addition, initial purchase orders (of GBP16,500) have been placed with EKF Diagnostic Holdings plc ("EKF") for PrimeStore(R) MTM sample collection devices. Adam Reynolds is also a Director of EKF and this order has been treated as a related party transaction. Product pricing for the agreement has been prepared on an arm's-length basis and there is no minimum volume requirement." | speedsgh | |
02/12/2020 07:13 | News of PrimeStore devices being used for Concepta's DNA testing service and its COVID-19 swab kit: | rivaldo | |
30/11/2020 09:10 | Mr Market up on the day with EKF buyers doing a Lord Lucan. I wonder why that is. As the wise man said - trading without stops is like driving without brakes. Conviction is the enemy of Truth! | tongosti | |
30/11/2020 07:59 | Morning Joe. | tongosti | |
30/11/2020 07:50 | Don`t forget to close your short on sfor old chap Mr Market has spoken Toodle pip | chris16041 | |
29/11/2020 15:24 | For goodness sake people - you don't mind a zillion bullish posts a day but all of a sudden you mind on the only one voice who's been telling you ON THE DAY that the path of least resistance is down not up. Speaks volumes innit - the crowd likes self confirmatory opinions. This board is testament to that. Live and let live! | tongosti | |
28/11/2020 16:02 | For interest these are the lateral flow tests being rolled out to hospital trusts | mirandaj | |
28/11/2020 13:26 | Filter him. | petewy | |
28/11/2020 10:55 | For goodness sake PAL - you are a trader which is fine but please dont waste all your words on here. We know your views which are fine but please dont go on and on . It is such a wsste of our time and yours . | 9degrees | |
28/11/2020 09:57 | Thought (big ask for you dear pal Joe) for the weekend: EKF is down about -24% since 9th of Nov (the Pfizer vaccine news day). FTSE All Share is +7.3% during the same period. There is a -31% relative underperformance. Those who have ever bothered (granted - they are not to be found in this FanClub) to crunch the numbers on near term relative strength signals would be far more cautious than the usual broken records who think are far smarter than the market. | tongosti | |
28/11/2020 09:28 | Have a look around these boards and see how many Joes like yourself have been outsmarted by yours truly. Patience sport patience. PS. Happy seeing a few crowd member/ been following an alternative approach. Who says they don't get anything?! | tongosti | |
28/11/2020 08:36 | Don`t normally post on these boards too many rampers and derampers This chap tongosi aka Mr Market appears to have set himself up as an expert In truth he is not very good. I happened to come across him on the Sfor board proudly announce he was opening a short.The shares went up almost 3% yesterday much to my delight Tongosti verses Sir Martin Sorrell no contest. I strongly advise you to close your short old boy before Mr Market does more damage to your wealth Toodle Pip | chris16041 | |
27/11/2020 16:03 | Glad seeing you're following me closely sport - I wonder why is that. Re sfor - opened up today so one needs to give the trade a few days or so. If it doesn't work, my stop is designed to bail me out at 2% of my account level. I am in control of risk - always and without fail. Mr Market is only in charge of gifts. Beat that Einstein! | tongosti | |
27/11/2020 15:37 | How's your Sfor short going Tongosti you must be desperate rocking up on here your negative isn't correlating with their rising share price enjoy. As for EKF I worry for you with what is likely coming next week | retirementfund | |
27/11/2020 15:26 | The number of bullish posts has been perfectly negatively correlated with the share price action since that now distant 82 level. Mr Market must love all this. | tongosti | |
27/11/2020 13:14 | Here is another thought for the day. EKF have already confirmed they intend to maintain a dividend policy. So, if we assume that the dividend will be the same, or greater than the current 1p dividend per share, what value might we also factor in for the potential in-specie dividend for Trellus Health? With the main thrust being, what the prospective dividend yield might be in relation to the current share price. Even if you want to be conservative and assume the total dividend (including Trellus Health) as amounting to only 2p, that gives a prospective yield of over 3% (based on the current mid price). Of course this does not then account for the growth on offer from a successful IPO of Trellus, and subsequently the direct exposure to the digital health opportunity, which is experiencing rapid rates of growth, increased investor interest, and attracting increasing amounts of corporate activity. | wan | |
27/11/2020 09:07 | Wilmdav...The IDS card test looks like an unbranded Abbott BionaxNow. The unbranded cassette could be anybody's given the similarities they all have. Anyway, apart from the share price reaction highlighting the potential exposure to the rapid expansion in testing that's currently taking place, I cannot see any EKF connection with those particular devices. Hopefully though, EKF may yet benefit from the rapid expansion in antigen testing too via ATM (as well as extraction-less testing), and ultimately the fact that antigen testing results in confirmatory PCR tests. | wan | |
27/11/2020 08:49 | edit to my post above - but overall the negative effects on testing revenues are probably not as much as the market currently assumes. | wan | |
27/11/2020 08:43 | Great post Wan I have exactly the same view the market has the exact reverse thought process as to what is actually happening regards testing. EKF are playing a cautious approach around upgrades and waiting to see everything come through and in place before they announce which I totally support. If this is correct the share price will appreciate rapidly between now and the trading update in early Jan. AIMHO GLA BTG | btgman | |
27/11/2020 08:26 | With vaccines on the horizon, probably like many others I have been challenging myself as to what level of Covid-19 testing will be required on initial and wider roll out of vaccines. There is no doubt in my mind that testing is currently going in the opposite direction to what the market currently appears to think, albeit I appreciate the market is looking beyond the here and now (and thereby may be underestimating the current growth/expansion in testing). A thought that has been going through my mind, is what if you develop symptoms even if you have received the vaccine? Then obviously you will still need to be tested to decipher whether it's flu or Covid-19, or indeed something else such as a mutation. In short, if you are symptomatic, having received a vaccine or not, you will still need to be tested, which will almost certainly be via a PCR test. Back to the current testing expansion. By now everyone is aware of the current expansion of antigen testing, and indeed imminent acceleration in the expansion of antigen testing. The following, demonstrates how antigen testing, will result in a PCR test i.e. a sample being sent to the lab - New Covid-19 asymptomatic testing site starts at the University of Birmingham 26 Nov 2020 Government-backed asymptomatic testing site to open at the University of Birmingham to help protect people most at risk . Students will be encouraged to get tested during the first week of December using Lateral Flow Devices. If they receive a negative test, they are advised to return home immediately. Should a student test positive they will then need to book a confirmatory PCR and have to self-isolate for 10 days, still with enough time to return home for Christmas. Back to vaccines. In combination with the PCR test scenario's I highlight above, antibody testing will go hand-in-hand with any vaccine roll-out, for testing the effectiveness post-vaccination and testing to learn how long immunity lasts. In short, antibody testing is likely to see a dramatic increase in demand. So, to my mind a key consideration with EKF is, to what degree PCR testing reduces, in comparison to now, and to what degree the antibody testing demand will have, compared to 'nothing' now. Again, we can only guess, but overall the negative effects on testing revenues are probably not as much as the market currently assumes. Factor in that any vaccine roll-out will assist a further rebound in the core business, then it's probably why the CEO remarked as he did regarding the share price reaction. Not to mention the prospects for Trellus Health (and any other partnership opportunities). | wan |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions